

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

MDA-MB-157

RRID:CVCL_0618

Type: Cell Line

Proper Citation

RRID:CVCL_0618

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0618

Proper Citation: RRID:CVCL_0618

Description: Cell line MDA-MB-157 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast carcinoma

Defining Citation: [PMID:730202](#), [PMID:833871](#), [PMID:1961733](#), [PMID:3518877](#), [PMID:4412247](#), [PMID:4471183](#), [PMID:9671407](#), [PMID:10862037](#), [PMID:10969801](#), [PMID:11044355](#), [PMID:11343771](#), [PMID:12353263](#), [PMID:12800145](#), [PMID:15153330](#), [PMID:15677628](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20679594](#), [PMID:21778573](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:28889351](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: African American., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-MB-157

Synonyms: MDA-MB157, MDAMB157, MDA-157, MDA157, MB 157, MB157, MD Anderson-Metastatic Breast-157

Cross References: BTO:BTO_0006218, CLO:CLO_0007544, CLO:CLO_0007632, EFO:EFO_0001206, CLDB:cl3400, CLDB:cl3401, AddexBio:C0006020/4986, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ATCC:CRL-7721, ATCC:HTB-24, BCRJ:0319, BioGRID_ORCS_Cell_line:556, BioSample:SAMN03472739, BioSample:SAMN03473083, BioSample:SAMN10988196, cancercellines:CVCL_0618, CCRID:1101HUM-PUMC000077, Cell_Model_Passport:SIDM00529, ChEMBL-Cells:ChEMBL3308759, ChEMBL-Targets:ChEMBL1075496, CLS:305280, Cosmic:687492, Cosmic:809234, Cosmic:871144, Cosmic:897421, Cosmic:904375, Cosmic:925338, Cosmic:934535, Cosmic:979714, Cosmic:1010921, Cosmic:1017166, Cosmic:1018462, Cosmic:1027052, Cosmic:1044207, Cosmic:1044228, Cosmic:1046954, Cosmic:1047692, Cosmic:1136372, Cosmic:1176640, Cosmic:1287919, Cosmic:1289393, Cosmic:1477429, Cosmic:1523776, Cosmic:1603217, Cosmic:1609468, Cosmic:1995501, Cosmic:2009506, Cosmic:2301527, Cosmic-CLP:925338, DepMap:ACH-000621, DepMap:ACH-001120, ECACC:92020422, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:925338, GEO:GSM73731, GEO:GSM115112, GEO:GSM186435, GEO:GSM186436, GEO:GSM217585, GEO:GSM219942, GEO:GSM350548, GEO:GSM421871, GEO:GSM783948, GEO:GSM783970, GEO:GSM827192, GEO:GSM844591, GEO:GSM847399, GEO:GSM847492, GEO:GSM887293, GEO:GSM888368, GEO:GSM1053729, GEO:GSM1172881, GEO:GSM1172977, GEO:GSM1238139, GEO:GSM1374648, GEO:GSM1374649, GEO:GSM1401671, GEO:GSM1670079, IARC_TP53:18370, LiGeA:CCLE_925, LINCS_HMS:50324, LINCS_HMS:50328, LINCS_LDP:LCL-1484, LINCS_LDP:LCL-1916, PharmacDB:MDAMB157_898_2019, PRIDE:PXD005292, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_0618, PubChem_Cell_line:CVCL_0618, SLKBase:3596, Wikidata:Q54904578

ID: CVCL_0618

Record Creation Time: 20220427T220755+0000

Record Last Update: 20260913T004832+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-157.

Warning: Discontinued: BCRJ; 0319

Population: African American., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Data and Source Information

Usage and Citation Metrics

We found 416 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Vendramin R, et al. (2026) Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome. *Immunity*, 59(5), 1398.

Dommer AP, et al. (2026) Cyclin E modulates vulnerability to CDC7 kinase inhibition. *Oncogenesis*, 15(1).

Luo L, et al. (2026) CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. *Nature communications*, 17(1), 619.

Harper NW, et al. (2025) RNA Pol II inhibition activates cell death independently from the loss of transcription. *Cell*.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. *Frontiers in oncology*, 15, 1549282.

Kwiatkowski N, et al. (2025) CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers. *Cell chemical biology*, 32(4), 556.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. *Cell reports. Medicine*, 6(12), 102478.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1275.

Chu Y, et al. (2025) A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2. *Nature biotechnology*.

Lin WD, et al. (2024) A novel long non-coding RNA MIR4500HG003 promotes tumor metastasis through miR-483-3p-MMP9 axis in triple-negative breast cancer. *Cell death & disease*, 15(5), 310.

Waas M, et al. (2024) Droplet-based proteomics reveals CD36 as a marker for progenitors in mammary basal epithelium. *Cell reports methods*, 4(4), 100741.

Trekitkarnmongkol W, et al. (2024) eEF1A2 promotes PTEN-GSK3 β -SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. *Science signaling*, 17(826), eadh4475.

Jinesh GG, et al. (2024) C19MC drives nucleolar invasion of mitochondria and meiotic nuclear division in human cancers. *iScience*, 27(11), 111132.

Lin CH, et al. (2023) Carboxyl-terminal modulator protein facilitates tumor metastasis in triple-negative breast cancer. *Cancer gene therapy*, 30(3), 404.

Xie X, et al. (2023) Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines. *Biomedicines*, 11(3).

Liang Y, et al. (2023) Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer. *Acta pharmaceutica Sinica. B*, 13(4), 1686.

Musheyev D, et al. (2023) Inhibition of ERK signaling for treatment of ERK?? positive TNBC. *PloS one*, 18(5), e0283047.

Roche S, et al. (2023) Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer. *PloS one*, 18(3), e0282512.

Saatci O, et al. (2023) Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification. *Cell death and differentiation*, 30(5), 1305.

Liu Y, et al. (2023) Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. *Cell research*, 33(5), 389.